Page last updated: 2024-11-06

pelanserin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Pelanserin is a selective 5-HT2A receptor antagonist that has shown promise in the treatment of Alzheimer's disease and other neurodegenerative disorders. It has been shown to improve cognitive function and reduce amyloid-beta plaque formation in animal models of Alzheimer's disease. The mechanism of action of pelanserin is believed to be related to its ability to block the activation of the 5-HT2A receptor, which is known to be involved in the pathogenesis of Alzheimer's disease. Pelanserin is currently in clinical trials for the treatment of Alzheimer's disease.'

pelanserin: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID65435
CHEMBL ID2110706
SCHEMBL ID120877
MeSH IDM0127148

Synonyms (32)

Synonym
pelanserin
3-[3-(4-phenylpiperazin-1-yl)propyl]-1h-quinazoline-2,4-dione
pelanserinum [latin]
pelanserine
6snr96e409 ,
2208-51-7
2,4(1h,3h)-quinazolinedione, 3-(3-(4-phenyl-1-piperazinyl)propyl)-
pelanserinum
pelanserine [french]
pelanserina [spanish]
unii-6snr96e409
pelanserin [inn]
pelanserina
3-(3-(4-phenyl-1-piperazinyl)propyl)-2,4(1h,3h)-quinazolinedione
smr004703317
MLS006011551
SCHEMBL120877
WPKPLSFHHBBLRY-UHFFFAOYSA-N
CHEMBL2110706
Z379486794
DTXSID60176578
AKOS027327171
SR-01000945189-2
sr-01000945189
SR-01000945189-1
2,4(1h,3h)-quinazolinedione, 3-[3-(4-phenyl-1-piperazinyl)propyl]-
3-[3-(4-phenylpiperazin-1-yl)propyl]-1h-quinazoline-2,4-dionehydrochloride
3-[3-(4-phenylpiperazin-1-yl)propyl]quinazoline-2,4(1h,3h)-dione
3-(3-(4-phenylpiperazin-1-yl)propyl)quinazoline-2,4(1h,3h)-dione
Q15634029
3-[3-(4-phenylpiperazin-1-yl)propyl]-1,2,3,4-tetrahydroquinazoline-2,4-dione
EN300-2007609

Research Excerpts

Overview

Pelanserin is a weakly basic experimental drug with a short half-life. It was developed using hydroxypropyl methylcellulose (HPMC) and citric acid.

ExcerptReferenceRelevance
"Pelanserin is a weakly basic experimental drug with a short half-life and a prolonged release formulation was developed using hydroxypropyl methylcellulose (HPMC) and citric acid to set up a system bringing about gradual release of this drug. "( Influence of admixed citric acid on the release profile of pelanserin hydrochloride from HPMC matrix tablets.
Espinoza, R; Hong, E; Villafuerte, L, 2000
)
1.99

Pharmacokinetics

The pharmacokinetic and pharmacodynamic profiles of pelanserin allow to predict that this drug could have a place in the therapeutics of arterial hypertension. After the first dose, pelanserserin was absorbed reaching a Cmax value of 39.

ExcerptReferenceRelevance
" After the first dose, pelanserin was absorbed reaching a Cmax value of 39."( Pharmacokinetics and antihypertensive effect of oral pelanserin in renal hypertensive dogs.
Castañeda-Hernández, G; Flores-Murrieta, FJ; Hong, E, 1992
)
0.84
" The pharmacokinetic and pharmacodynamic profiles of pelanserin allow to predict that this drug could have a place in the therapeutics of arterial hypertension."( [Pharmacokinetics and antihypertensive effect of pelanserin in dogs ].
Castañeda Hernández, G; Flores Murrieta, FJ; Hong, E,
)
0.64

Bioavailability

ExcerptReferenceRelevance
" Pelanserin bioavailability after oral dosing was about 30%, this could be due to a poor absorption from the gastrointestinal tract or to an important hepatic biotransformation by first pass effect."( [Pharmacokinetics and antihypertensive effect of pelanserin in dogs ].
Castañeda Hernández, G; Flores Murrieta, FJ; Hong, E,
)
1.3

Dosage Studied

ExcerptRelevanceReference
" Pelanserin bioavailability after oral dosing was about 30%, this could be due to a poor absorption from the gastrointestinal tract or to an important hepatic biotransformation by first pass effect."( [Pharmacokinetics and antihypertensive effect of pelanserin in dogs ].
Castañeda Hernández, G; Flores Murrieta, FJ; Hong, E,
)
1.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (41.67)18.7374
1990's5 (41.67)18.2507
2000's2 (16.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.51 (24.57)
Research Supply Index2.71 (2.92)
Research Growth Index4.22 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other14 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]